Com a expiração da patente do Ozempic em março de 2026, o Brasil deu um passo significativo na democratização do acesso a tratamentos modernos para obesidade: a Anvisa aprovou o Ozivy, primeiro medicamento injetável à base de semaglutida produzido em solo nacional, desenvolvido pela farmacêutica EMS. O evento não é apenas regulatório — é um momento em que a soberania farmacêutica encontra uma demanda de saúde pública crescente, abrindo caminho para que mais brasileiros possam acessar uma classe de medicamentos que redefiniu o tratamento do sobrepeso no mundo.
Folha De Pernambuco
· May 26, 2026
· health
· 1 min read
High
Sourcing: Verified
Brazil's Anvisa approves first domestically-produced GLP-1 weight-loss injection
◉
Health & Medicine
2834 related articles
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% match
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% match
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% match
Brazil's obesity guidelines shift focus from weight loss to disease ma…
Correio Braziliense · 90% match
Medical Expert Warns of Tirzepatide Risks, Emphasizes Need for Profess…
UNIPAR · 90% match
Related Coverage
Folha de S.Paulo · Aug 26
Ônibus escolar cai em ribanceira e deixa duas crianças feridas em SC
Ônibus escolar com dez crianças caiu dez metros em ribanceira em Santa Catarina. Duas crianças ficaram feridas e foram h…
G1 · Aug 26 Incêndio em hospital do Paquistão mata ao menos 15 bebêsPelo menos 15 recém-nascidos morreram em incêndio no hospital PIMS em Islamabad, causado por falha no sistema de ar-cond…
G1 · Aug 26 Zelador agredido com paulada evolui na UTI, mas segue internado no DFZelador agredido há 15 dias por homem em situação de rua apresenta melhora clínica na UTI, respondendo a estímulos e com…
Google News · Aug 26 Diretor do Atlético-MG acusa Kaio Jorge de 'maldade e deslealdade' após lance polêmicoDirigente do Atlético-MG acusa Kaio Jorge de jogada maldosa e desleal que resultou em queda do zagueiro Ruan Tressoldi, …
Bias & Framing
⚖
Straightforward reporting of regulatory approval with minimal bias; uses colloquial term 'canetas emagrecedoras' consistently and presents factual information about patent expiration and approval process.
Bias Direction
center
Confidence
HIGH
Neutral informational framing focused on regulatory milestone and procedural details; uses accessible language ('canetas emagrecedoras') that reflects local terminology without editorializing.
canetas emagrecedoras (weight-loss pens) - colloquial but not inherently loaded, reflects common usage
Patient or consumer perspective on drug access/affordability
Healthcare provider commentary on domestic production benefits
Comparison of pricing between domestic and imported versions
Public health implications or concerns about GLP-1 medication use
Industry expert analysis on competitive landscape
Geopolitical Impact
🌎
Brazil's domestic GLP-1 production capability reduces pharmaceutical import dependency and positions it as a regional generics hub, while challenging Novo Nordisk's market dominance in Latin America.
Escalation Risk
low
Confidence
HIGH
Brazil
Latin America
Global pharmaceutical markets
Brazil strengthens pharmaceutical sovereignty and generic drug manufacturing capacity, reducing reliance on Danish/foreign producers. This enhances Brazil's regional soft power in healthcare and positions it competitively against multinational pharma dominance in emerging markets.
Similar to India's rise as a generic drug manufacturer in the 1990s-2000s, enabling affordable medications across the Global South while challenging patent-holder monopolies.
Economic Lens
📈
Brazil's domestic GLP-1 market expands with Anvisa approval of EMS's Ozivy semaglutide, enabling local production post-Ozempic patent expiration and reducing import dependency.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical manufacturing
Healthcare/Biotechnology
Medical devices
Generic drug production
Healthcare services
Brazilian consumers gain access to more affordable domestically-produced GLP-1 weight-loss treatments, reducing reliance on expensive imported alternatives and potentially lowering medication costs through increased competition as additional variants enter the market.
Demonstrates successful patent expiration transition and regulatory capacity for complex biologics. May incentivize local pharmaceutical R&D investment and generic production. Potential future price regulation discussions as market competition increases with 6+ additional variants under review.